文献速递头颈外科

头颈部鳞状细胞癌患者初治与复发肿瘤间PD-L1、PD-L2及EGFR表达的差异:一项回顾性研究

Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study.
PubMed 文献 · Head Neck · 2025-03-28

该回顾性研究分析了79对初治与复发头颈部鳞状细胞癌(HNSCC)肿瘤的PD-L1、PD-L2及EGFR表达,并采用倾向性评分匹配分析非复发患者的实验室指标。结果显示30%–40%的肿瘤对中PD-L1、PD-L2及EGFR表达发生变化,早期复发患者的免疫细胞PD-L1阳性率显著更高。结论认为初治肿瘤的免疫检查点表达不能反映复发肿瘤,免疫细胞PD-L1表达升高可能导致HNSCC早期复发。

要点

  • 79对初治与复发HNSCC肿瘤中,30%–40%的肿瘤对PD-L1、PD-L2及EGFR表达发生变化。
  • 早期复发患者的免疫细胞PD-L1阳性率显著高于无早期复发者,肿瘤细胞PD-L1阳性率无此差异。
  • 一线治疗后白细胞、中性粒细胞、淋巴细胞、单核细胞计数及淋巴细胞-单核细胞比值显著降低,与是否复发无关。

核心结论

  • 初治肿瘤中包括PD-L1在内的免疫检查点表达不能反映复发肿瘤的表达情况。
  • 免疫细胞中PD-L1表达升高可能导致HNSCC早期复发。

研究设计与样本

  • 回顾性研究,分析79对初治与复发HNSCC肿瘤的实验室检查结果及PD-L1、PD-L2、EGFR组织表达。
  • 对非复发患者另采用倾向性评分匹配分析实验室检查结果。
  • PD-L1与PD-L2表达采用肿瘤比例评分(TPS)和联合阳性评分(CPS)评估,EGFR采用H评分评估。

主要发现

  • 30%–40%的肿瘤对中PD-L1、PD-L2及EGFR表达发生变化。
  • 早期复发患者的免疫细胞PD-L1阳性率显著高于非早期复发患者,而肿瘤细胞PD-L1阳性率无显著差异。
  • 无论是否复发,一线治疗后患者的白细胞、中性粒细胞、淋巴细胞、单核细胞计数及淋巴细胞-单核细胞比值均显著降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of anti-PD-1 and EGFR therapies for head and neck squamous cell carcinoma (HNSCC) can be predicted using various markers; however, the stability of these markers remains unclear. METHODS: In this retrospective study, laboratory findings and tissue expression of PD-L1, PD-L2, and EGFR were analyzed in 79 paired naive and recurrent HNSCC tumors. Laboratory findings were also analyzed in nonrecurrent patients using a propensity score-matched analysis. PD-L1 and PD-L2 expression levels were assessed using tumor proportion score (TPS) and combined positive score (CPS), whereas EGFR was evaluated using the H-score. RESULTS: White blood cell, neutrophil, lymphocyte, and monocyte counts and lymphocyte-monocyte ratios were significantly lower in the patients after the first-line treatment regardless of recurrence. PD-L1, PD-L2, and EGFR expression changed in 30%-40% of tumor pairs. Immune but not tumoral PD-L1 positivity rates were significantly higher in the patients with early recurrence. CONCLUSIONS: The expression of immune checkpoints including PD-L1 in naive tumors does not reflect those in recurrent tumors. Increasing PD-L1 expression in immune cells may cause early recurrence of HNSCC.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Sato R, Inoue T, Wakisaka R, et al. Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study. Head Neck. 2025. PMID: 40156197. doi:10.1002/hed.28151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。